Intercept Announces Departure of Chief Financial Officer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P on track for muted open as Middle East tensions weigh; AI stocks boost Nasdaq
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- Fulcrum Therapeutics to merge with Slate Medicines in all-stock deal
- Piper Sandler Starts SoFi Technologies (SOFI) at Overweight
H.C. Wainwright Upgrades Intercept Pharmaceuticals (ICPT) to Neutral
March 12, 2021 6:15 AM ESTH.C. Wainwright analyst Ed Arce upgraded Intercept Pharmaceuticals (NASDAQ: ICPT) from Sell to Neutral with a price target of $21.00 (from $25.00).
The analyst comments "We downgraded ICPT to Sell on February 23 when it traded at about $30 per share (prior close $29.86). The shares hit a multi-year low of $19.33 on March 4, and are now close to $21, largely on recent macroeconomic optimism, in our view. Our underlying thesis (NASH program has little to no risk-adjusted value, and PBC franchise faces substantial risks) has not changed. However, given the drop in... More
